Table 2.
Baseline characteristics of patients who continued MTX and those who switched
| Characteristics | Patients switching medication N = 93 |
Patients continuing MTX N = 90 |
|---|---|---|
| Demographics | ||
| Age (years) | 52±13 | 54±14 |
| Male (%) | 45 (48) | 48 (53) |
| Baseline disease scores | ||
| Swollen joint count | 4 (2–7) | 3 (2–6) |
| Tender joint count | 6 (3–10) | 4 (2–9) |
| Oligoarthritis (%) | 58 (62) | 50 (56) |
| Polyarthritis (%) | 35 (38) | 40 (44) |
| PASI | 2.6 (0.8–4.9) | 2.4 (0.6–4.5) |
| Pain VAS | 51±24 | 46±26 |
| Global VAS | 51±27 | 46±25 |
| LEI >0 (%) | 33 (37) | 36 (39) |
| HAQ total score | 0.8 (0.6–1.3)* | 0.6 (0.3–0.9) |
| DAPSA | 22.7±10.3 | 20.4±10.6 |
| MDA (%) | 2 (2) | 6 (7) |
Results shown as mean±SD, n (%) or median (IQR). Baseline clinical data of one patient missing, questionnaires of three patients missing.
*p<0.05.
DAPSA, Disease Activity index for PSoriatic Arthritis; HAQ, Health Assessment Questionnaire; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Scale.